Amylyx Pharmaceuticals (AMLX) Accounts Payables (2021 - 2026)

Amylyx Pharmaceuticals' Accounts Payables history runs 6 years deep, the most recent figure standing at $3.5 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 26.63% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $3.5 million (down 26.63% YoY), while the FY2025 annual figure was $3.5 million, up 19.73% from the prior year.
• Accounts Payables was $3.5 million for Q1 2026 at Amylyx Pharmaceuticals, roughly flat from $3.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $24.7 million in Q2 2023 to a low of $1.5 million in Q3 2024.
• Historically, Accounts Payables has averaged $8.6 million across 5 years, with a median of $6.3 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables slumped 86.68% in 2024, then jumped 259.05% in 2025.
• A 5-year view of Accounts Payables shows it stood at $6.3 million in 2022, then soared by 252.58% to $22.1 million in 2023, then plunged by 86.68% to $2.9 million in 2024, then gained by 19.73% to $3.5 million in 2025, then advanced by 0.28% to $3.5 million in 2026.
• The last three Accounts Payables figures came in at $3.5 million (Q1 2026), $3.5 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.